TY - JOUR
T1 - Comparison of an Enzyme Immunoassay Versus Mass Spectrometry-based Assay for the Quantitative Determination of the Procollagen Type I N-terminal Propeptide in Rat Serum
AU - Dzieciatkowska, Monika
AU - Copeland, Marci
AU - You, Jinsam
AU - Wery, Jean Pierre
AU - Wang, Mu
PY - 2009
Y1 - 2009
N2 - Traditionally, antibody-based assays, such as enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA)and radioimmunoassay (RIA), are the primary tool for the targeted quantification of a specific protein. An antibody-based assay can berun at high-throughput and has extraordinary sensitivity and specificity. In the cases where antibody-based assays exist, the processof validating biomarker candidates can be relatively straightforward. However, the antibody-based approach is limited by the lack ofavailability of antibodies with high specificity. The development of a high quality antibody-based assays can be costly, time-consumingand a resource-intensive effort. Another disadvantage of antibody-based assays is that they often do not discriminate closely relatedisoforms. While the antibody development is central to the success of antibody-based platform, mass spectrometry (MS) providesalternative and complementary approach to existing antibody-based assays. The MS-based assays are becoming very popular forquantitative candidates proteins detection in a complex biological mixture.In the present paper, an in-house developed mass spectrometry (MS)-based assay was compared to a commercially available EIA inreproducibility, measurement accuracy, and dynamic range using rat procollagen type-I N-terminal propeptide (P1NP) as a model.
AB - Traditionally, antibody-based assays, such as enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA)and radioimmunoassay (RIA), are the primary tool for the targeted quantification of a specific protein. An antibody-based assay can berun at high-throughput and has extraordinary sensitivity and specificity. In the cases where antibody-based assays exist, the processof validating biomarker candidates can be relatively straightforward. However, the antibody-based approach is limited by the lack ofavailability of antibodies with high specificity. The development of a high quality antibody-based assays can be costly, time-consumingand a resource-intensive effort. Another disadvantage of antibody-based assays is that they often do not discriminate closely relatedisoforms. While the antibody development is central to the success of antibody-based platform, mass spectrometry (MS) providesalternative and complementary approach to existing antibody-based assays. The MS-based assays are becoming very popular forquantitative candidates proteins detection in a complex biological mixture.In the present paper, an in-house developed mass spectrometry (MS)-based assay was compared to a commercially available EIA inreproducibility, measurement accuracy, and dynamic range using rat procollagen type-I N-terminal propeptide (P1NP) as a model.
KW - Immunoassay
KW - Mass spectrometry
KW - Procollagen type-I N-terminal propeptide
KW - Selected-reaction-monitoring
UR - http://www.scopus.com/inward/record.url?scp=84865135680&partnerID=8YFLogxK
U2 - 10.4137/pri.s3454
DO - 10.4137/pri.s3454
M3 - Article
AN - SCOPUS:84865135680
SN - 1178-6418
VL - 2
SP - 33
EP - 38
JO - Proteomics Insights
JF - Proteomics Insights
IS - 1
ER -